

## What is MyGeneHistory?

A digital tool that collects patient personal and family cancer history, identifies whether patient meets national guidelines for hereditary cancer testing, and shares results instantly and securely with your practice.

# 2X

Patients that utilize MyGeneHistory<sup>®\*</sup> are **more than twice as likely** to complete testing.<sup>1</sup>

\*MyGeneHistory<sup>®</sup> assessment version with patient education

1. Richard N. Waldman, MD, Mark S. DeFrancesco, MD, John P. Feltz, MD, Daniel S. Welling, MD, Wade A. Neiman, MD, Melissa M. Pearlstone, MD, Christine A. Marraccini, MD, DanaKaranik, RN, Elaine Mielcarski, CNM, Logan Schneider, MS, Lauren Lenz, MS, Edith C. Smith, DNP, Katherine Johansen Taber, PhD, and Royce T. Adkins, MD, FACS, Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing. *Obstetrics & Gynecology* 145(2):p 177-185, February 2025.

Myriad<sup>®</sup>  
genetics

Myriad Genetics, Inc. / 322 North 2200 West Salt Lake City, UT 84116 / [www.myriad.com](http://www.myriad.com)

©2025 Myriad Genetics, Inc. Myriad Genetics, MyGeneHistory and their respective logos are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. WHMHGCPVBRO 0825

Myriad  
genetics<sup>®</sup>

## MyGeneHistory<sup>®</sup>

Your all-in-one digital tool for gathering patient personal and family cancer history.



## Why is it valuable?

- ✔ Patients that utilize MyGeneHistory® are more than twice as likely to complete testing<sup>1</sup>
- ✔ Streamlines the test ordering process by pre-populating patient data and saves you time
- ✔ Incorporates recent societal guidelines to help ensure no high-risk patient is missed during the screening process
- ✔ Reduces risk of errors through seamless results and ordering process
- ✔ Includes an initial assessment of breast cancer risk for eligible patients

## Key Features



Prepopulates the online test order form for **faster ordering and reducing the risk of errors** within the provider portal



~**6-10 minutes** for patients to complete questionnaire



Incorporates recent **guidelines from three leading groups** for accurate patient identification



Includes pre-test **patient education video** for patients who need extra education on the benefits of hereditary cancer testing



**Immediate notification** in provider portal when patient completes questionnaire



Receive a simple answer for **whether your patient meets guidelines** for hereditary cancer testing



Includes **Tyrer-Cuzick breast cancer risk assessment** within results

## How It Works

- 1 Practice distributes MyGeneHistory® to patients via email, text, and/or QR code
- 2 Patient answers all personal and family health history questions
- 3 Patient and provider are immediately notified if patient meets national guidelines for testing
- 4 Patient and provider discuss results and proceed to testing if appropriate
- 5 Prepopulates patient's personal and family history into the online test order form for seamless ordering

**Hereditary Cancer Risk Screening Results** MyGeneHistory™  
NOT A LAB REPORT

Name: Penny Patient      Provider: Danielle Doctor, MD      Assessment taken: 10/11/23  
 DOB: 10/10/1980      Previously tested: No      Report generated: 10/11/23  
 Sex at birth: Female      Patient phone: (887) 654-3210      Patient email: penny.patient@email.com      3:49:30 PM  
 Ancestry: Other

HEREDITARY CANCER TESTING	COMMENTS
<p><b>Patient meets criteria</b></p> <p style="color: green; font-size: 2em;">✔</p> <p>Offer hereditary cancer testing</p>	Based on the patient's answers, they appear to meet society guidelines or other miscellaneous criteria for hereditary cancer testing. This patient may be a candidate for Myriad's MyRisk® Hereditary Cancer Test. Make sure to discuss these results with your patient.

**TYRER-CUZICK BREAST CANCER RISK ESTIMATES**

Lifetime risk: 9.8%	Patients with a Tyrer-Cuzick lifetime breast cancer risk of 20% or greater may be eligible for modified breast imaging surveillance. (Please note, these risk estimates do not take into account the patient's breast density. If this information is available, and your patient is 40 years or older, please refer to the included table to identify your patient's breast density-adjusted Tyrer-Cuzick version 8 lifetime breast cancer risk estimate.)
5-year risk: 1.2%	

Below is a summary of the guideline(s) and specific criteria your patient meets for hereditary cancer testing.

Guideline	Qualifying history
NCCN	<ul style="list-style-type: none"> <li>Guideline: A first or second degree relative of the patient has a diagnosis of triple negative breast cancer (includes invasive or DCIS) at any age Relationship: Aunt Maternal</li> <li>Guideline: A first or second degree relative with breast cancer (includes invasive or DCIS) at or under age 50 Relationship: Aunt Maternal</li> </ul>
USPSTF	<ul style="list-style-type: none"> <li>Guideline: First or second degree relative with breast cancer under age 50 Relationship: Aunt Maternal</li> </ul>

Personal history		
Cancer history None reported	Colon polyp history None reported	Sample information Blood transfusion <12 months: No Bone marrow recipient: No

**Myriad** genetics  
© 2025 Myriad Genetics, Inc. Myriad and MyGeneHistory and their respective logos are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes of diagnosis, counseling and testing on patient identified in the report and members of his or her family. EMHGPCRSBLRPT 0325  
 322 North 2200 West, Salt Lake City, Utah 84116 | Ph: 1-800-469-7423 | Fx: 801-584-3615      Page 1 of 4